Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
DSG3-CAART by Cabaletta Bio for Pemphigus Vulgaris: Likelihood of Approval
DSG3-CAART is under clinical development by Cabaletta Bio and currently in Phase II for Pemphigus Vulgaris. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Cabaletta Bio's DSG3-CAART?
DSG3-CAART is a gene-modified cell therapy commercialized by Cabaletta Bio, with a leading Phase II program in Pemphigus Vulgaris. According...